<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04461535</url>
  </required_header>
  <id_info>
    <org_study_id>ADOPA study</org_study_id>
    <nct_id>NCT04461535</nct_id>
  </id_info>
  <brief_title>Outcomes of AVS With or Without ACTH Stimulation in PA</brief_title>
  <official_title>Adrenal Venous Sampling With or Without Adrenocorticotropic Hormone Stimulation in Primary Aldosteronism: an Outcome-based Randomized, Double-blind Trial (ADOPA Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of different procedures of AVS(with or without ACTH stimulation) on the&#xD;
      long-term outcomes of patients with PA&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, double-blinded study involving 200 patients with primary&#xD;
      aldosteronism(PA) who completed AVS.&#xD;
&#xD;
      All paticipants will be randomized into ACTH-stimulated group(Intervention group,n=100) and&#xD;
      ACTH-unstimulated group(Control group,n=100) and to compare the long-term outcomes of&#xD;
      patients with PA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the rate of complete biochemical remission between two groups</measure>
    <time_frame>At 12 months of follow-up.</time_frame>
    <description>Blood was drawn to measure aldosterone, renin and potassium.According to PASO criteria, outcomes of adrenalectomy for unilateral primary aldosteronism were classified into complete, partial, and absent success, for both clinical and biochemical outcomes.The proportion of complete biochemical remission according to PASO consensus criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete clinical remission</measure>
    <time_frame>At 12 months of follow-up.</time_frame>
    <description>The proportion of complete clinical remission according to PASO consensus criteria.Clinical outcomes were determined by the blood pressure response to treatment and the number and dosage of antihypertensive medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily defined doses (DDD) of antihypertensive agents</measure>
    <time_frame>At 12 months of follow-up.</time_frame>
    <description>Daily defined doses (DDD) of antihypertensive agents at 12th months of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful catheterization.</measure>
    <time_frame>At baseline</time_frame>
    <description>Calculate the rate of successful catheterization.Successful catheterization was defined as SI≥2 without ACTH stimulation or SI≥3 with ACTH stimulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>At baseline and 12 month of follow-up.</time_frame>
    <description>Record the occurrence of adverse events, including adrenal venous hemorrhage and related adrenal insufficiency, hypertensive urgencies, anaphylactic shock, venous thrombosis, pulmonary embolism, ect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The health-related quality of life</measure>
    <time_frame>At baseline and 12 months of follow-up.</time_frame>
    <description>Compare the quality of life score between two groups,using EuroQol-5 Dimension Visual Analogue Scale (VAS) score.The minimum and maximum values are 0 and 100,respectively. And higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bilateral adosterone inhibiton (BAS) in AVS</measure>
    <time_frame>At baseline</time_frame>
    <description>calculate the BAS rate in AVS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Primary Aldosteronism</condition>
  <arm_group>
    <arm_group_label>AVS with ACTH stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients divided into AVS with ACTH stimulation group need to undergo stimulation with a continuous cosyntropin infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVS without ACTH stimulation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients divided into AVS without ACTH stimulation group take the same procedure of AVS with a continuous saline infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adrenocorticotropic hormone</intervention_name>
    <description>Patients divided into Intervention group need to undergo stimulation with a continuous cosyntropin infusion (50 μg/h started 30 minutes before sampling during AVS). Right and left adrenal venous blood and corresponding peripheral venous blood should be sampled sequentially.</description>
    <arm_group_label>AVS with ACTH stimulation</arm_group_label>
    <other_name>ACTH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1.Inclusion criteria: Patients who meet the following criterion can be included in this&#xD;
        study.&#xD;
&#xD;
          1. Hypertension patients with positive PA screening (ARR&gt;20) and at least one positive PA&#xD;
             confirmatory test (PAC-post CCT&gt;110pg/ml, PAC-post SSIT &gt;80pg/ml, or PAC-post&#xD;
             FST&gt;60pg/ml);&#xD;
&#xD;
          2. Willing to undergo AVS;&#xD;
&#xD;
          3. Understand the whole process of the trial and voluntarily accept randomized grouping,&#xD;
             intervention and follow-up;&#xD;
&#xD;
          4. Voluntarily participate in the study and sign the informed consent form;&#xD;
&#xD;
          5. Aged between 18-70, male or female, with legal capacity;&#xD;
&#xD;
        2.Exclusion criteria: Patients with one of the following conditions will be excluded in&#xD;
        this study:&#xD;
&#xD;
          1. Pregnant or lactating women;&#xD;
&#xD;
          2. Refusal to undergo unilateral adrenalectomy;&#xD;
&#xD;
          3. Allergic to ACTH or contrast media;&#xD;
&#xD;
          4. PA combined with Cushing syndrome (including subclinical Cushing): Cortisol was&#xD;
             greater than 140nmol/ L after 1mg DST;&#xD;
&#xD;
          5. Familial PA;&#xD;
&#xD;
          6. Treatment with glucocorticoids and cannot be stopped;&#xD;
&#xD;
          7. Complicated with disease which contraindicated to unilateral adrenalectomy or&#xD;
             seriously interfere with subsequent treatment of PA or health-related quality of life&#xD;
             assessment, such as severe heart disease (including pacemaker implantation), severe&#xD;
             cardiac dysfunction, severe anemia (Hb&lt;60g/L), stroke or acute coronary syndrome&#xD;
             within 3 months, severe ascites and liver cirrhosis, malignant tumors;&#xD;
&#xD;
          8. Alcoholics, drug users, and mentally disabled patients;&#xD;
&#xD;
          9. CT does not exclude pheochromocytoma or cortical carcinoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qifu Li, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>the Chongqing Primary Aldosteronism Study (CONPASS) Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qifu Li, PhD</last_name>
    <phone>+86 023-89011552</phone>
    <email>liqifu@yeah.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affilated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qifu Li, M.D., PhD.</last_name>
      <phone>023-89011552</phone>
      <email>liqifu@yeah.net</email>
    </contact>
    <contact_backup>
      <last_name>Ying Song, M.D.</last_name>
      <phone>023-89011552</phone>
      <email>shuiyunying@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916. doi: 10.1210/jc.2015-4061. Epub 2016 Mar 2.</citation>
    <PMID>26934393</PMID>
  </results_reference>
  <results_reference>
    <citation>Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, Tanabe A; Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society. Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. Endocr J. 2011;58(9):711-21. Epub 2011 Aug 9.</citation>
    <PMID>21828936</PMID>
  </results_reference>
  <results_reference>
    <citation>Deinum J, Groenewoud H, van der Wilt GJ, Lenzini L, Rossi GP. Adrenal venous sampling: cosyntropin stimulation or not? Eur J Endocrinol. 2019 Sep;181(3):D15-D26. doi: 10.1530/EJE-18-0844. Review.</citation>
    <PMID>31176302</PMID>
  </results_reference>
  <results_reference>
    <citation>Buffolo F, Monticone S, Williams TA, Rossato D, Burrello J, Tetti M, Veglio F, Mulatero P. Subtype Diagnosis of Primary Aldosteronism: Is Adrenal Vein Sampling Always Necessary? Int J Mol Sci. 2017 Apr 17;18(4). pii: E848. doi: 10.3390/ijms18040848. Review.</citation>
    <PMID>28420172</PMID>
  </results_reference>
  <results_reference>
    <citation>Dekkers T, Prejbisz A, Kool LJS, Groenewoud HJMM, Velema M, Spiering W, Kołodziejczyk-Kruk S, Arntz M, Kądziela J, Langenhuijsen JF, Kerstens MN, van den Meiracker AH, van den Born BJ, Sweep FCGJ, Hermus ARMM, Januszewicz A, Ligthart-Naber AF, Makai P, van der Wilt GJ, Lenders JWM, Deinum J; SPARTACUS Investigators. Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial. Lancet Diabetes Endocrinol. 2016 Sep;4(9):739-746. doi: 10.1016/S2213-8587(16)30100-0. Epub 2016 Jun 17.</citation>
    <PMID>27325147</PMID>
  </results_reference>
  <results_reference>
    <citation>Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, Satoh F, Amar L, Quinkler M, Deinum J, Beuschlein F, Kitamoto KK, Pham U, Morimoto R, Umakoshi H, Prejbisz A, Kocjan T, Naruse M, Stowasser M, Nishikawa T, Young WF Jr, Gomez-Sanchez CE, Funder JW, Reincke M; Primary Aldosteronism Surgery Outcome (PASO) investigators. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017 Sep;5(9):689-699. doi: 10.1016/S2213-8587(17)30135-3. Epub 2017 May 30.</citation>
    <PMID>28576687</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2020</study_first_posted>
  <last_update_submitted>August 22, 2021</last_update_submitted>
  <last_update_submitted_qc>August 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Qifu Li</investigator_full_name>
    <investigator_title>Professor.Qifu Li</investigator_title>
  </responsible_party>
  <keyword>primary aldosteronism</keyword>
  <keyword>adrenal venous sampling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
    <mesh_term>Melanocyte-Stimulating Hormones</mesh_term>
    <mesh_term>beta-Endorphin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

